Reviewed by Christian Espinosa, MBA, CISSP · Founder & CEO
Published April 2026 · Last reviewed May 2026
The Med Device Cyber Podcast · with Dr. Basant Bajpai · April 3, 2026 In this episode of The Med Device Cyber Podcast, host Trevor Slattery with guest Dr. Basant Bajpai, CEO of Compliance MedQar, delve into the crucial role of early Quality Management System (QMS) implementation for medical device manufacturers. Dr. Bajpai emphasizes that early adoption of a simple, traceable QMS from the concept and R&D stages is vital to avoid costly “reverse documentation” and ensure regulatory compliance. The discussion highlights the common mistake of companies opting for overly complex QMS tools when a simpler, automated system is more effective for building a strong foundation and enabling scalability. The conversation then shifts to the innovative integration of AI into QMS, explaining how AI can enhance efficiency by drafting documentation, flagging non-compliance with standards like 21 CFR Part 820, EU MDR, and MDSAP, and identifying gaps in clinical evidence. However, both speakers stress the critical importance of a "human in the loop" to validate AI-generated content, especially for traceability and evidence of compliance, addressing concerns about AI hallucinating critical documentation like penetration test reports. The episode also touches on the growing trend of regulatory bodies, particularly in the EU, adopting AI for submission reviews to improve efficiency, while noting the FDA
Key Takeaways
- Start QMS implementation as early as possible, ideally during the concept or R&D stage, to establish a strong, traceable foundation and avoid costly reverse documentation later.
- Opt for simple, automated QMS tools that fit your regulatory journey and ensure traceability, rather than complex or "fancy" systems that may be difficult to implement with limited resources.
- Utilize AI as a tool to enhance QMS efficiency by drafting documentation, checking compliance against regulations like 21 CFR Part 820 and EU MDR, and flagging gaps, but always maintain a 'human in the loop' for validation and accountability.
- Recognize that traceability and evidence of compliance must remain a manual, human-controlled process to prevent AI from fabricating critical artifacts like penetration test reports.
- Prioritize cybersecurity early in the product development lifecycle, as it is a critical component of quality and regulatory compliance, and late integration can lead to significant delays and costs.
- Understand that regulatory bodies are increasingly adopting AI for reviewing submissions, signaling a future where both medical device manufacturers and regulators leverage AI, necessitating a clear understanding of its appropriate and responsible use.
Listen on mdcpodcast.com · Watch on YouTube
Listen to this episode
Want help applying this to your own device program?
Blue Goat Cyber is a specialist medical device cybersecurity firm: 250+ FDA submissions, zero rejections. If anything in this conversation hit close to home, book a 30-minute strategy session - no cost, no obligation.